Wanted capital : 250.000 €
Minimum investment : 60 €
Development phase : Seeding
Risks : The investment in the capital of an unlisted company presents a risk of partial or total loss of invested capital, as well as a risk of illiquidity.
Founded in 2009 by members of the Brossel family, CC & C is a Société Anonyme (SA) with a capital of 395.075 € with 87 shareholders (march 2018). The patent belongs to the company.
We rely on the latest discoveries in the field of oncology including physical oncology and mechanobiology, to develop a treatment against pancreatic cancer. To do this, we have developed a patented technology for exerting a stress field on the tumor, with the aim of:
Learn more about our technology ...
The next year will be busy conducting the Proof of Efficacy, that is to say, the experimental validation that our technology actually makes it possible to reduce the volume of the tumors, or to make them benign. The experiment will be conducted on mice to which a human pancreatic tumor has been grafted.
Learn more about Proof of Efficacy ...
The sum collected must be used to build the device that will deliver a magnetic field around the pancreas of the mice, to make the nanoparticles we need and to conduct the experiment. We will then process the results, write an article and have it published. Meanwhile, the operating costs of the company continue, and must be covered.
The experiments should be conducted through two partnerships, one in the United States, with the prestigious Stanford University, the other with a European consortium around the Faculty of Medicine of Bichat in Paris. These partnerships give us access to public subsidies. Obtaining these funds depends in particular on the financial health of CC & C. In concrete terms, we are asked to have € 200,000 in the bank. This fundraising is really crucial for our development.
Learn more about our business strategy ...
Make an appointment with the leader of the company.
We call you back at the dates and times that suit you.
Make an appointment